Immunohistochemical study of apoptosis markers and involvement of chemokine CXCR4 in skin Merkel cell carcinoma

Journal of the European Academy of Dermatology and Venereology

Volumn 20, Issue 10, 2006, Pages 1220-1225

  Tucci, M G ^a   Lucarini, Guendalina ^b   Giangiacomi, M ^b   Zizzi, A ^b   Criante, P ^b   Ricotti, G ^a   Biagini, G ^b  

^a INRCA   (Italy)

^b UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

Author keywords

Apoptosis; Chemokine CXCR4; Immuno histochemistry; Merkel cell carcinoma

Indexed keywords

ANTINEOPLASTIC AGENT; APOPTOSIS INHIBITOR; CHEMOKINE RECEPTOR CXCR4; KI 67 ANTIGEN; MUTANT PROTEIN; PROTEIN ANTIBODY; PROTEIN BCL 2; PROTEIN P16; PROTEIN P53; SURVIVIN;

AGED; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIMB AMPUTATION; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MALE; MERKEL CELL TUMOR; METASTASIS INHIBITION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REOPERATION; SKIN CARCINOMA; TREATMENT PLANNING;

APOPTOSIS; BIOLOGICAL MARKERS; CARCINOMA, MERKEL CELL; CELL DIVISION; CYCLIN-DEPENDENT KINASE INHIBITOR P16; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MICROTUBULE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTORS, CXCR4; SKIN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 33750301120     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2006.01764.x     Document Type: Article

References (27)

1. Connelly TJ, Cribier B, Brown TJ, Yanguas I. Complete spontaneous regression of Merkel carcinoma: A review of ten reported cases. Dermatol Surg 2000; 26: 853-856.
2. Takenaka H, Kishimoto S, Shibagaki R, Nagata M, Yasuno G. Merkel cell carcinoma with partial spontaneous regression: An immunohistochemical, ultrastructural and TUNEL labeling study. Am J Dermatopathol 1997; 19: 614-618.
3. Tope WD, Sangueza OP. Merkel cell carcinoma histopathology, immunohistochemistry and cytogenic analysis. J Dermatol Surg Oncol 1994; 10: 648-652.
4. Agelli M, Klegg LX. Epidemiology of primary Merkel cell carcinoma in the United States. J Am Acad Dermatol 2003; 49: 832-841.
5. Meeuwissen JA, Bourne RG, Kearsley JH. The importance of postoperative radiation therapy in the treatment of Merkel cell carcinoma. Int J Radiation Oncol Biol Phys 1995; 31: 325-331.
6. Healy E, Angus B, Lawrence CM, Rees JL. Prognostic value of ki67 antigen expression in basal cell carcinomas. Br J Dermatol 1995; 133: 737-741.
7. Kroemer G. The proto-oncogene Bcl-2 and its role in regulating apoptosis. Nat Med 1997; 3: 614-620.
8. Fanidi A, Harrington EA, Evan GIK. Cooperative interaction between c-myc and bcl-e protooncogenes. Nature 1992; 359: 554-556.
9. Kanter-Lewensohn L, Hedblad MA, Wejde J, Larsson O. Immunohistochemical markers for distinguishing Spitz nevi from malignant melanomas. Mod Pathol 1977; 10: 917-920.
10. Cerroni L, Kerl H. Aberrant bcl-2 protein expression provides a possible mechanism of neoplastic cell growth in cutaneous basal cell carcinoma. J Cutan Pathol 1994; 21: 398-403.
11. Levine AJ, Momand J, Finley CA. The p53 tumor suppressor gene. Nature 1991; 351: 543-456.
12. Iggo R, Gatter K, Bartek J. Increased expression of mutant forms of p53 oncogene in primary lung cancer. Lancet 1990; 335: 675-679.
13. Ambrosini G, Adida C, Altieri D. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 1997; 3: 917-921.
14. Ambrosini G, Adida C, Sirugo G, Altieri DC. Induction of apoptosis and inhibition of cell proliferation by survivin gene targeting. J Biol Chem 1998; 273: 11177-11182.
15. Chiodino C, Cesinaro AM, Ottani D et al. Expression of the novel inhibitor of apoptosis survivin in normal and neoplastic skin. J Invest Dermatol 1999; 113: 415-418.
16. Ho A, Dowdy SF. Regulation of G (1) cell-cycle progression by oncogenes and tumor-suppressor genes. Curr Opin Genet Dev 2002; 12: 47-52.
17. Cairns P, Poladcik TJ, Eby Y et al. Frequency of homozygous deletion at p16/CDKN2 in primary human tumors. Nat Genet 1995; 11: 210-212.
18. Goldstein AM, Tucker MA. Screening for CDKN2A mutations in hereditary melanoma. J Natl Cancer Inst 1997; 89: 676-678.
19. Rollins BJ. Chemokines. Blood 1997; 90: 909-928.
20. Kato M, Kitayama J, Kazama S, Nagawa H. Expression pattern of CXC chemokine receptor-4 is correlated with lymph node metastasis in human invasive ductal carcinoma. Breast Cancer Res 2003; 5: 144-150.
21. Muller A, Homey B, Soto H et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001; 410: 50-56.
22. Poulsen M. Merkel-cell carcinoma of the skin. Lancet Oncol 2004; 5: 593-599.
23. Feinmesser M, Halpern M, Fenig E et al. Expression of the apoptosis-related oncogenes bcl-2, bax, and p53 in Merkel cell carcinoma: Can they predict treatment response and clinical outcome? Hum Pathol 1999; 30: 1367-1372.
24. Kennedy MM, Blessing K, King G, Kerr KM. Expression of bcl-2 and p53 in Merkel cell carcinoma. An immunohistochemical study. Am J Dermatopathol 1996; 18: 273-277.
25. Schmidt M, Janssen K, Dockhorn-Dworniczak B et al. P53 abnormalities are rare events in neuroendocrine (Merkel cell) carcinoma of the skin. An immunohistochemical and SSCP analysis. Virchows Arch 1997; 430: 233-237.
26. Uchida D, Begum N, Almofti A et al. Possible role of stromal-cell derived factor-1/CXCR4 signaling on lymph node metastasis of oral squamous cell carcinoma. Exp Cell Res 2003; 290: 289-302.
27. Murakami T, Maki W, Cardones AR et al. Expression of CXC chemokine receptor-4 enhances the pulmonary metastatic potential of murine B16 melanoma cells. Cancer Res 2002; 62: 7328-7334.